Learn more about whether Ionis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

William Blair lifted their Q1 2026 earnings estimates for shares of Ionis Pharmaceuticals in a research note issued on ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...

Jones Financial Companies Lllp boosted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by ...

William Blair analyst Myles Minter reiterated a Buy rating on Ionis Pharmaceuticals (IONS – Research Report) today. The company’s shares opened ...

Ionis Pharmaceuticals (IONS) and Ono Pharmaceutical announced that the two companies have entered into a license agreement in which Ono obtains ...

Ionis Pharmaceuticals (NASDAQ:IONS) underwent analysis by 7 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The table below provides a snapshot of their ...

Also Read: Ionis Pharmaceuticals Q4 Revenue Growth Exceeds Guidance, Forecasts Over $600 Million In 2025 Sales Sapablursen received FDA Fast Track designation and orphan drug designation in 2024.

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...

Ionis Pharmaceuticals Partners With Japan-Based Ono Pharmaceutical For Rare Blood Disease Drug In Over $800 Million Deal On Tuesday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical ...

Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains ...